TP53 mutation hits energy metabolism and increases glycolysis in breast cancer

Hajnalka Papp, Lőrinc Sándor Pongor, Gyöngyi Munkácsy, Gergő Horváth, Ádám Nagy, Attila Ambrus, Péter Hauser, András Szabó, László Tretter, Balázs Győrffy

Oncotarget · 2016 · 68 citations · 37 references

DOIFull text

Open access

Concepts

Abstract

// Hajnalka Harami-Papp 1, * , Lőrinc S. Pongor 1, 3, * , Gyöngyi Munkácsy 1 , Gergő Horváth 2 , Ádám M. Nagy 2 , Attila Ambrus 2 , Péter Hauser 3 , András Szabó 3 , László Tretter 2 , Balázs Győrffy 1 1 MTA TTK Lendület Cancer Biomarker Research Group, H-1117, Budapest, Hungary 2 Semmelweis University, Department of Medical Biochemistry, H-1094, Budapest, Hungary 3 Semmelweis University, Second Department of Pediatrics, H-1094, Budapest, Hungary * These authors have contributed equally to this work Correspondence to: Balázs Győrffy, email: gyorffy.balazs@ttk.mta.hu László Tretter, email: tretter.laszlo@med.semmelweis-univ.hu Keywords: glycolytic efficiency, breast cancer, Warburg effect, next generation sequencing Received: May 24, 2016      Accepted: August 13, 2016      Published: August 25, 2016 ABSTRACT Promising new hallmarks of cancer is alteration of energy metabolism that involves molecular mechanisms shifting cancer cells to aerobe glycolysis. Our goal was to evaluate the correlation between mutation in the commonly mutated tumor suppressor gene TP53 and metabolism. We established a database comprising mutation and RNA-seq expression data of the TCGA repository and performed receiver operating characteristics (ROC) analysis to compare expression of each gene between TP53 mutated and wild type samples. All together 762 breast cancer samples were evaluated of which 215 had TP53 mutation. Top up-regulated metabolic genes include glycolytic enzymes ( e.g. HK3, GPI, GAPDH, PGK1 , ENO1 ), glycolysis regulator ( PDK1 ) and pentose phosphate pathway enzymes ( PGD, TKT , RPIA ). Gluconeogenesis enzymes ( G6PC3, FBP1 ) were down-regulated. Oxygen consumption and extracellular acidification rates were measured in TP53 wild type and mutant breast cell lines with a microfluorimetric analyzer. Applying metabolic inhibitors in the presence and absence of D-glucose and L-glutamine in cell culture experiments resulted in higher glycolytic and mitochondrial activity in TP53 mutant breast cancer cell lines. In summary, TP53 mutation influences energy metabolism at multiple levels. Our results provide evidence for the synergistic activation of multiple hallmarks linking to these the mutation status of a key driver gene.

References

37